ZVRA Q3 2024 Earnings — Zevra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ZVRAZevra Therapeutics, Inc.

$618M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M+27.6% YoY

Gross Profit

$1M37.7% margin

Operating Income

-$27M-739.0% margin

Net Income

-$33M-899.2% margin

EPS (Diluted)

$-0.69

QoQ Revenue Growth

-16.9%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$192M

Total Liabilities

$122M

Stockholders' Equity

$70M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$3M	+27.6%
Gross Profit	$1M	$3M	-49.4%
Operating Income	-$27M	-$15M	-77.7%
Net Income	-$33M	-$10M	-220.5%